1mon
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf
SAB Biotherapeutics (NASDAQ:SABS) used an appearance at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results